JB Chemicals & Pharmaceuticals Ltd., the fastest growing pharmaceutical company in India has emerged in a new avatar, retaining its core value of being ‘Good People for Good Health’.
The company announced its new identity on Friday. With the emerging healthcare industry and changing needs of the customers, JB has endeavored to redefine the spread of good health in India.
JB aims to support healthcare providers and enrich patients’ lives in innovative new ways while also remaining committed to its core values of integrity, trust and reliability built over 45 years.
Announcing the change of identity for JB – Good People for Good Health, Nikhil Chopra, CEO and Director, JB, said, “Over 45 years, we at JB have built a strong foundation of integrity, trust and credibility.
We are now taking the next leap. Going to be more agile, with the trend towards becoming simpler.”
He added, “Our offerings and capabilities become more diverse to meet the evolving needs of our customers, our manufacturing processes are becoming more robust and absorbed, and our approach to the healthcare industry is more globally progressive.
We are adapting ourselves to be more responsive to the needs of the healthcare world.”
Chopra continued, “While we are changing in many ways, we are not changing the solid foundation of JB. Our new identity has a simple, concrete look that reflects our way of thinking and behaving. It is ‘good’. Symbolizes our belief in being ‘People for Good Health’.”
Speaking on JB’s financial achievements, JB’s CEO said, “Owing to our consistently outperformance, we have maintained the sales momentum in Q4 FY 2021-22 and ended it on a positive note despite the challenging external environment.
Our domestic business has maintained its stellar performance with double-digit growth and we continue to maintain our position among the top 30 fastest growing companies in the Indian Pharmaceutical Market (IPM). “
The company registered a revenue of Rs 2,424 crore in FY 2021-22 as compared to Rs 2,043 crore in FY 2020-21, registering a growth of 19 per cent.
Sales were up 18 per cent in the previous quarter and domestic formulations continued their market-beating performance by posting 30 per cent growth.
As of MAT/MAT March 2022, JB grew at the rate of 29 per cent while the market grew at 18 per cent and as of the last quarter of FY 2022, it grew at the rate of 21 per cent, while the market grew at the rate of 10 per cent. Hui.
In addition, there were six new product launches in the last quarter of FY 2022, with over 15 major new launches excluding product line extensions.
JB’s international business has also seen a bounce back in the fourth quarter of FY 2021-22, showing double digit growth across sectors with a year-on-year growth rate of 9 per cent.
A strong uptick has been recorded in South Africa and API driven by the contract manufacturing business.
Meeting the evolving needs of the customers (patients), JB has been adopting emerging new technologies and acquiring leading pharma brands.
The recent acquisition of Sangem has helped JB gain rank and statistics among IPM’s top-30 brands. Similarly, with the acquisition of Ajmarda in April 2022, JB’s rank in the IPM is likely to rise further.
JB has emerged as the fastest growing Indian pharmaceutical company and is among the top 30 pharma companies in IPM with a remarkable growth rate of 19 per cent in the financial year 2021-22.
JB’s five domestic brands have featured in the top 100 in the cardiac therapy segment with four brands (including Ajmarda) in IPM’s top 300. JB is currently ranked 12th in the IPM in the Gastrointestinal segment.
It has over 350 brands with 20 major therapeutic categories. Its brands are available in 600,000 pharmacies in almost every pin code area in India.
The top 300 of IPM includes five domestic JB brands, with Rantac (Anti-ulcer) ranked 45th in the IPM ranking and the gastro-intestinal segment at 6th.
In addition, Cilacar (anti-hypertensive) ranks at 52 and cardiac segment ranks 4, with Cilacar-T (anti-hypertensive) rank at 203 and cardiac segment at rank 22.
Along with this Metrogil (Amoebicide) is ranked 194th in IPM rank, Nicardia (Anti-Hypertensive) at 240th and Cardiac Segment at 30th.
Its seven manufacturing facilities in India comply with the world’s highest standards meeting stringent international regulatory requirements across the globe.
It is one of the few Indian pharma companies to use osmotic-controlled release oral delivery system technology.
JB has established an unmatched technological leadership in lozenges as a drug delivery format and is today one of the world’s top five manufacturers of medicinal and herbal lozenges.
It has over 40 highest global accreditations for its manufacturing process, including certifications from the US, UK, EU, Australia, South Africa, Russia/independent countries and Australia.
JB exports a wide range of formulations to over 40 regulated and semi-regulated markets.
JB is one of the top 15 companies in the South African regulated market, with a strong public and private presence.
In Russia, JB has over 30 years of brand equity and a direct presence with a field force in the high growth OTC segment. It is a key partner for global pharma innovators and global multinationals.